Voyager Therapeutics Ownership
| VYGR Stock | USD 3.88 0.21 5.13% |
Shares in Circulation | First Issued 2014-06-30 | Previous Quarter 58 M | Current Value 58 M | Avarage Shares Outstanding 31.4 M | Quarterly Volatility 15.9 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Voyager |
Voyager Stock Ownership Analysis
About 64.0% of the company outstanding shares are owned by institutional investors. The company has Price to Book (P/B) ratio of 0.71. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Voyager Therapeutics recorded a loss per share of 1.13. The entity had not issued any dividends in recent years. Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts. Voyager Therapeut operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 101 people. For more information please call Sandrock MD at 857 259 5340 or visit https://www.voyagertherapeutics.com.Voyager Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Voyager Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Voyager Therapeutics backward and forwards among themselves. Voyager Therapeutics' institutional investor refers to the entity that pools money to purchase Voyager Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Great Point Partners Llc | 2024-12-31 | 826.8 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 447.1 K | Northern Trust Corp | 2024-12-31 | 418.7 K | Prudential Financial Inc | 2024-12-31 | 330.3 K | Globeflex Capital, L.p. | 2024-12-31 | 291.3 K | Goldman Sachs Group Inc | 2024-12-31 | 291.3 K | Wellington Management Company Llp | 2024-12-31 | 261.3 K | Fiduciary Trust Co | 2024-12-31 | 259.4 K | Jpmorgan Chase & Co | 2024-12-31 | 241.6 K | Armistice Capital, Llc | 2024-12-31 | 5.4 M | Blackrock Inc | 2024-12-31 | 5.4 M |
Voyager Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Voyager Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Voyager Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Voyager Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Voyager Therapeutics Outstanding Bonds
Voyager Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Voyager Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Voyager bonds can be classified according to their maturity, which is the date when Voyager Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| VMC 715 30 NOV 37 Corp BondUS929160AG40 | View | |
| VULCAN MATLS 45 Corp BondUS929160AV17 | View | |
| VULCAN MATLS 39 Corp BondUS929160AT60 | View | |
| VULCAN MATLS 45 Corp BondUS929160AS87 | View |
Voyager Therapeutics Corporate Filings
8K | 11th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 24th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Pair Trading with Voyager Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Voyager Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Voyager Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Voyager Stock
Moving against Voyager Stock
| 0.91 | LUCD | Lucid Diagnostics | PairCorr |
| 0.83 | WM | Waste Management | PairCorr |
| 0.68 | GE | GE Aerospace | PairCorr |
| 0.5 | PLX | Protalix Biotherapeutics | PairCorr |
| 0.44 | PG | Procter Gamble | PairCorr |
The ability to find closely correlated positions to Voyager Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Voyager Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Voyager Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Voyager Therapeutics to buy it.
The correlation of Voyager Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Voyager Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Voyager Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Voyager Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Voyager Stock Analysis
When running Voyager Therapeutics' price analysis, check to measure Voyager Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Voyager Therapeutics is operating at the current time. Most of Voyager Therapeutics' value examination focuses on studying past and present price action to predict the probability of Voyager Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Voyager Therapeutics' price. Additionally, you may evaluate how the addition of Voyager Therapeutics to your portfolios can decrease your overall portfolio volatility.